Renovo is a biopharmaceutical product company and a leader in the discovery and development of drugs to reduce scarring, improve wound healing and enhance tissue regeneration.
Renovo has a portfolio of clinical programmes including potential pharmaceutical drugs to reduce scarring (eg Prevascar), a potential Class III medical device in the EU to reduce adhesions between the tendons and tendon sheath following the surgical repair of lacerated digital tendons (Adaprev) and a potential cosmetic ingredient (Juvidex) for the acceleration of healing and the reduction of redness in injured skin.
Further information is contained in the Products section of our website. Commercial enquires into our extensive Intellectual Property estate are welcome via partnering@renovo.com.
Printer-friendly version